Clinical Trial Update: Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating capecitabine and temozolomide for recurrent pituitary adenomas; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pituitary Adenoma

Drugs mentioned

• Capecitabine (capecitabine)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Recurrent Pituitary Adenomas | Phase 2 | Status: TERMINATED | Results posted: 2022-08-09